Advicenne
ALDVI | PA
Overview
Corporate Details
- ISIN(s):
- FR0013296746 (+1 more)
- LEI:
- 969500YT5VMEYAYODW34
- Country:
- France
- Address:
- 262 RUE DU FAUBOURG SAINT-HONORE, 75008 PARIS
- Website:
- https://advicenne.com
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
For more than 10 years, Advicenne has been dedicated to developing innovative, effective and safe treatments for people living with rare renal diseases who have very limited therapeutic options. Thanks to our expertise in reformulation and drug delivery, we are uniquely positioned to develop and make available innovative treatments for both children and adults with rare renal diseases. At Advicenne we are dedicated to improving patients’ daily health and life. Our employees in France and the United States are committed to tackle the challenge of high unmet medical need to improve quality of life for patients and their caregivers. Sibnayal® (combination of Potassium citrate and Potassium bicarbonate) was in 2021 approved by the European Medicine Agency and MHRA.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Advicenne.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-28 07:30 |
Regulatory News Service
Inside Information / Other news releases
|
English | 164.8 KB | |
| 2025-07-28 07:30 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 178.7 KB | |
| 2025-07-25 07:30 |
Earnings Release
Inside Information / Other news releases
|
English | 177.4 KB | |
| 2025-07-25 07:30 |
Earnings Release
Informations privilégiées / Autres communiqués
|
French | 190.6 KB | |
| 2025-05-16 08:00 |
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
|
French | 114.8 KB | |
| 2025-04-29 18:00 |
Registration Form
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rap…
|
French | 182.1 KB | |
| 2025-04-29 18:00 |
Registration Form
Annual financial and audit reports / Terms of availability of the annual financ…
|
English | 152.3 KB | |
| 2025-03-27 19:12 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 324.3 KB | |
| 2025-03-27 19:12 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 336.8 KB | |
| 2025-01-23 18:30 |
Earnings Release
Informations privilégiées / Information sur chiffre d’affaires annuel
|
French | 233.9 KB | |
| 2025-01-23 18:30 |
Earnings Release
Inside Information / Information on annual revenues
|
English | 243.6 KB | |
| 2024-12-19 18:00 |
M&A Activity
Inside Information / Other news releases
|
English | 196.5 KB | |
| 2024-12-19 18:00 |
M&A Activity
Informations privilégiées / Autres communiqués
|
French | 163.2 KB | |
| 2024-11-28 18:00 |
Report Publication Announcement
Informations privilégiées / Autres communiqués
|
French | 192.1 KB | |
| 2024-11-28 18:00 |
Report Publication Announcement
Inside Information / Other news releases
|
English | 190.8 KB |
Automate Your Workflow. Get a real-time feed of all Advicenne filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Advicenne via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-10-04 | N/A | Other | Other | 1,452,282 | 3,499,999.62 EUR |
| 2023-10-04 | N/A | Other | Buy | 41,493 | 99,998.13 EUR |
| 2023-10-02 | N/A | Other | Other | 414,937 | 999,998.17 EUR |
| 2023-09-21 | N/A | Other | Sell | 22,336 | 22.34 EUR |
| 2023-09-15 | N/A | Other | Sell | 134,492 | 13.45 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Herantis Pharma Oyj | Finland | HRTIS | |
| Hiron-Trade Investments & Industrial Buildings Ltd. | Israel | HRON | ||
|
Human Stem Cells Institute PJSC | Russian Federation | ISKJ | |
|
Human Xtensions Ltd. | Israel | HUMX | |
|
Hybrigenics SA | France | ALHYG | |
|
Hyloris Pharmaceuticals SA | Belgium | HYL | |
|
Ikonisys S.A. | France | ALIKO | |
|
IMCB PJSC | Russian Federation | GEMA | |
|
Immunic AG | United States of America | IMUX | |
| Incanthera plc | United Kingdom | N/A |